188 related articles for article (PubMed ID: 35359368)
21. Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC.
Zhou N; Velez MA; Bachrach B; Gukasyan J; Fares CM; Cummings AL; Lind-Lebuffe JP; Akingbemi WO; Li DY; Brodrick PM; Yessuf NM; Rettinger S; Grogan T; Rochigneux P; Goldman JW; Garon EB; Lisberg A
Lung Cancer; 2021 Nov; 161():34-41. PubMed ID: 34507111
[TBL] [Abstract][Full Text] [Related]
22. Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study.
Koelzer VH; Rothschild SI; Zihler D; Wicki A; Willi B; Willi N; Voegeli M; Cathomas G; Zippelius A; Mertz KD
J Immunother Cancer; 2016; 4():13. PubMed ID: 26981243
[TBL] [Abstract][Full Text] [Related]
23. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
[TBL] [Abstract][Full Text] [Related]
24. Sarcoid-like reaction of the extrathoracic lymph node in a patient with lung adenocarcinoma treated with pembrolizumab.
Takamori S; Furubayashi N; Taguchi K; Matsubara T; Fujishita T; Ito K; Yamaguchi M; Toyozawa R; Seto T; Negishi T; Nakamura M; Okamoto T
Thorac Cancer; 2021 Jul; 12(14):2122-2125. PubMed ID: 34002950
[TBL] [Abstract][Full Text] [Related]
25. Case Report: Sarcoid-Like Reactions and Tertiary Lymphoid Structures Following Dual Checkpoint Inhibition in a Patient with Early-Stage Lung Adenocarcinoma.
Zhao X; Yue D; Qian J; Zhang L; Song J; Zhang B; Zhang C; Sun L; Ma Y; Zhang H; Wang C
Front Immunol; 2022; 13():794217. PubMed ID: 35173719
[TBL] [Abstract][Full Text] [Related]
26. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
27. The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Yang Y; Luo H; Zheng XL; Ge H
Clin Transl Oncol; 2021 Jun; 23(6):1117-1127. PubMed ID: 33211281
[TBL] [Abstract][Full Text] [Related]
28. Toripalimab-Induced Dermatomyositis in a Patient with Metastatic Melanoma.
Lin J; Xue M; Gao M; Yu P; Han S
Dermatol Ther (Heidelb); 2020 Aug; 10(4):863-867. PubMed ID: 32445174
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P; Singh PK; Malik PS; Singh N
Curr Treat Options Oncol; 2020 Jul; 21(8):69. PubMed ID: 32720019
[TBL] [Abstract][Full Text] [Related]
30. Complete response induced by anti-PD-1-based immunotherapy with toripalimab in a patient with locally advanced lung adenocarcinoma who failed rapidly after concurrent chemoradiotherapy: A case report.
Xue W; Zhang T; Wang X; Duan J; Bi N
J Clin Pharm Ther; 2020 Dec; 45(6):1511-1514. PubMed ID: 32893899
[TBL] [Abstract][Full Text] [Related]
31. Sarcoidosis-like reactions in cancer patients treated with immune checkpoint inhibitors: experience in a Spanish hospital.
Torres-Jiménez J; Esteban-Villarrubia J; García-Abellás P; Cortés-Salgado A; Soria-Rivas A; Gajate-Borau P; Olmedo-García ME; Corral-de la Fuente E; Lage-Alfranca Y; Gómez-Rueda A; Benito-Berlinches A; Gorospe-Sarasua L; Garrido-López P
Clin Transl Oncol; 2021 Jul; 23(7):1474-1480. PubMed ID: 33433837
[TBL] [Abstract][Full Text] [Related]
32. Granulomatosis With Polyangiitis in a Patient on Programmed Death-1 Inhibitor for Advanced Non-small-cell Lung Cancer.
Sibille A; Alfieri R; Malaise O; Detrembleur N; Pirotte M; Louis R; Duysinx B
Front Oncol; 2019; 9():478. PubMed ID: 31245290
[No Abstract] [Full Text] [Related]
33. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy.
Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J
Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525
[TBL] [Abstract][Full Text] [Related]
34. An unusual case of immune-related gastritis in one patient receiving toripalimab therapy.
Chen X; Shi W
Immunotherapy; 2023 Apr; 15(5):335-342. PubMed ID: 36852424
[TBL] [Abstract][Full Text] [Related]
35. The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis.
Wang C; Qiao W; Jiang Y; Zhu M; Shao J; Wang T; Liu D; Li W
J Cell Physiol; 2020 May; 235(5):4913-4927. PubMed ID: 31693178
[TBL] [Abstract][Full Text] [Related]
36. [Incidence and Risk of PD-1/PD-L1 Inhibitor-associated Pneumonia in Advance Cancer Patients: A Meta-analysis].
Chen K; Sun B
Zhongguo Fei Ai Za Zhi; 2020 Nov; 23(11):927-940. PubMed ID: 33203196
[TBL] [Abstract][Full Text] [Related]
37. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
38. Lazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review.
Nie NF; Liu ZL; Feng MX; Liu L; Luo N; Li L; He Y
Ann Palliat Med; 2021 Jan; 10(1):210-219. PubMed ID: 33545758
[TBL] [Abstract][Full Text] [Related]
39. Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors.
Chu X; Zhao J; Zhou J; Zhou F; Jiang T; Jiang S; Sun X; You X; Wu F; Ren S; Zhou C; Su C
Lung Cancer; 2020 Dec; 150():76-82. PubMed ID: 33080551
[TBL] [Abstract][Full Text] [Related]
40. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
